Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

Development and validation of a stability-indicating HPTLC method for analysis of rupatadine fumarate in the bulk drug and tablet dosage form

Warianty tytułu
Języki publikacji
A simple, selective, precise and stability-indicating high-performance thin-layer chromatographic method for analysis of rupatadine fumarate, both as the bulk drug and in a tablet formulation, has been developed and validated. Aluminium foil TLC plates precoated with silica gel 60F 254 were used as stationary phase and toluene-methanol-triethylamine 4:1:0.2 ( v/v ) as mobile phase. A compact band ( R F 0.61 š 0.02) was obtained for rupatadine fumarate. Densitometric analysis was performed in absorbance mode at 264 nm. Linear regression analysis revealed a good linear relationship ( r 2 = 0.9992 š 0.0001) between peak area and concentration in the range 400-1400 ng band -1. The mean values š SD of the slope and intercept were 2.5471 š 0.005 and 1055.2 š 4.20, respectively. The method was validated for precision, recovery, and robustness. The limits of detection and quantitation were 66.63 and 201.91 ng band -1, respectively. Rupatadine fumarate was subjected to acid and alkaline hydrolysis, oxidation, and photochemical and thermal degradation and underwent degradation under all these conditions. Statistical analysis proved the method enables repeatable, selective, and accurate analysis of the drug. It can be used for identification and quantitative analysis of rupatadine fumarate in the bulk drug and in tablet formulations.
Opis fizyczny
Bibliogr. 13 poz., rys., tab.
  • [1] S.C. Sweetman (eds) Martindale — The Complete Drug Reference, Vol. I, Pharmaceutical Press, 2007, p. 533
  • [2] M. Merlos, M. Giral, D. Balsa, R. Ferrando, M. Queralt, A. Puigdemont, J. Garcia-Rafanell, and J. Forn, Pharmacol. Exp. Ther., 280 , 114–121 (1997)
  • [3] A. Gimenez-Arnau, R.M. Pujol, S. Ianosi, A. Kaszuba, A. Malbran, G. Poop, E. Donado, I. Perez, I. Izquierdo, and E. Arnaiz, Allergy, 62 , 539–546 (2007)
  • [4] D.R. Nogueira, F.B. D’Avila, C.M.B. Rolim, and S.L. Dalmora, Chromatographia, 66 , 915–919 (2007)
  • [5] M.J. Barbanoj, C. Garcia-Gea, R. Antonijoan, I. Isquierdo, E. Donado, I. Perez, A. Solans, and F. Jane, Hum. Psychopharmacol. Clin. Exp., 21 , 13–26 (2006)
  • [6] R. Caballero, C. Valenzuela, M. Longobardo, J. Tamargo, and E. Delpon, Br. J. Pharmacol., 128 , 1071–1081 (1999)
  • [7] International Conference on Harmonisation (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use (2005) Validation of Analytical Procedures: Text and Methodology Q2 (R1), 2005, pp. 1–13
  • [8] International Conference on Harmonisation (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use (2003) Stability Testing of New Drugs Substance and Products Q1A (R2), 2003, pp. 1–18
  • [9] M. Bakshi, S. Singh, J. Pharm. Biomed. Anal., 28 , 1011–1040 (2002)
  • [10] P.D. Sethi, HPTLC: Quantitative Analysis of Pharmaceutical Formulations, CBS Publications, New Delhi, 1996, pp. 162–165
  • [11] British Pharmacopoeia, International edn, Vol. II, HMSO, Cambridge, 2002, Appendix-112(IB)
  • [12] P.E. Wall, Thin-layer Chromatography (A Modern Practical Approach), VWR International, Poole, Dorset, 2005, pp 115–118
  • [13] E. Heftman, Chromatography — Fundamentals and Applications of Chromatography and Related Differential Migration Methods, 6th edn, 69A, Elsevier, Amsterdam, 2004, pp. 253–291.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.